COLLEGE of AMERICAN PATHOLOGISTS
Education

Multidisciplinary Breast Pathology Online Activities

Diagnosing and Classifying Hyperplasia, Atypical Hyperplasia, and Low-Grade DCIS (1.25 CME)

Breast cancer is a morphologically and clinically diverse disease. The successful treatment for the patient relies on an accurate diagnosis of the morphological changes. In this activity, you will learn to distinguish usual ductal hyperplasia from atypical ductal hyperplasia and low-grade ductal carcinoma in situ, as well as flat epithelial atypia from various columnar cell lesions. You will also learn the clinical significance and the current management of these diagnoses.

Diagnosing Breast Lesions (1.25 CME)

IHC studies are increasingly used to aid in the diagnostic evaluation of breast lesions. This activity will emphasize potential pitfalls in interpretation and will discuss both common as well as less recognized (but often more challenging) sources of diagnostic error. You will learn correlative morphological features to help you interpret confusing or indeterminate IHC results. You will also gain an understanding of the appropriate settings in which these IHC studies may be diagnostically helpful and an appreciation of their uses and limitations in daily practice.

HER2 Focused Update (1.25 CME)

In 2018, the American Society of Clinical Oncology and the CAP developed a focused update on human epidermal growth factor receptor 2 (HER2) testing in breast cancer. The focused update endorses the 2013 HER2 testing guidelines while addressing outstanding questions related to HER2 testing. The guidelines were updated again in 2023, reaffirming the 2018 ASCO/CAP guidelines for HER2 testing and acknowledging emerging evidence supporting the efficacy of T-DXd in this subset of HER2-negative breast cancers. The 2023 Update also introduces a new HER2 testing report comment to underscore the clinical relevance of distinguishing IHC 1+ from IHC 0 results, along with best practice recommendations in identifying these subtle differences. This activity addresses six clinical questions raised since the 2013 update and includes case studies that illustrate the practical application of what has been proposed in this update. A new clinical question was added to the course to reflect the 2023 HER2 Focused Update.

Invasive Breast Cancer and Risk of Recurrence Testing (1.5 CME)

Genomic testing for breast cancer recurrence risk has become an important part of clinical breast cancer care. This activity provides an overview of risk of recurrence testing used in the diagnosis and treatment of invasive breast cancer. Statistics on cancer recurrence and clinical outcomes with chemotherapy, including data from the TAILORx trial, are reviewed. The activity also provides the value and benefits of risk of recurrence testing, as well as how to determine which patients are good candidates for this testing. The different types of multigene assays and distinctions between them are reviewed, as well as an overview of IHC and protein profiling of cancer. The activity includes the American Society of Clinical Oncology and National Comprehensive Cancer Network clinical practice guidelines for use of biomarkers to guide decisions on adjuvant systemic therapy for women with invasive breast cancer and discusses the issues and concerns that continue to exist around risk of recurrence testing.